FGFR3 in Other Solid Tumors

In addition to bladder cancer, a number of other solid tumors have been reported to exhibit overexpression, mutation or fusion of FGFR3, including invasive breast carcinoma, squamous cell carcinoma of the lung, and squamous cell carcinoma of the head and neck.

In addition to playing a primary role in tumorigenesis, some preclinical studies have also demonstrated that FGFR3 can cause resistance to targeted therapies in melanoma, non-small cell lung cancer and breast cancer. For instance, FGFR3 signaling has been reported to be elevated and to induce resistance to vemurafenib, a B-RAF inhibitor, in an in vitro study of a vemurafenib-resistant melanoma cell line.